Drug updated on 4/18/2024
| Dosage Form | injectable (intravenous; 15.5 MBq/mL to 308.2 MBq/mL [0.42 mCi/mL to 8.33 mCi/mL]) |
| Drug Class | Radioactive diagnostic agents |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for use in positron emission tomography (PET) to visualize dopaminergic nerve terminals in the striatum for the evaluation of adult patients with suspected Parkinsonian syndromes (PS). Fluorodopa F 18 PET is an adjunct to other diagnostic evaluations.
Summary
- Fluorodopa F 18 is indicated for use in positron emission tomography to visualize dopaminergic nerve terminals in the striatum for evaluating adult patients with suspected Parkinsonian syndromes, serving as an adjunct to other diagnostic evaluations.
- Four systematic reviews/meta-analyses compared Fluorodopa F 18's safety and effectiveness with other diagnostic methods or radiopharmaceuticals within specific population subgroups.
- In young patients presenting with parkinsonian symptoms such as Dopamine Responsive Dystonia (DRD) and Juvenile Parkinsonism (JP), Fluorodopa F 18 PET scans provide a viable alternative when genetic testing is not feasible due to accessibility or cost issues. This radiopharmaceutical shows distinctive patterns of decreased uptake in JP cases, while DRD results are comparable to those in normal subjects.
- For brain tumor evaluation, particularly gliomas, Fluorodopa F 18 PET has shown superior effectiveness over traditional fluorine-18 fluorodeoxyglucose PET/CT due to its metabolic imaging capabilities with amino-acid radiotracers like itself.
- Studies found that the detection rate using Fluorodopa F 18 for recurrent Medullary Thyroid Carcinoma (MTC) was significantly higher than other modalities, regardless of serum calcitonin or CEA levels and calcitonin doubling time, suggesting broader applicability across patient subgroups.
- Lastly, among various PET tracers used for detecting brain tumors including 11 C-methionine, 11 C-choline, etc., radiolabelled amino acid tracers like Fluorodopa F 18 showed the highest diagnostic performance, indicating its superiority over others, especially in terms of prognostic value for glioma patients.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Fluorodopa F 18 Prescribing Information. | 2019 | The Feinstein Institutes for Medical Research, Manhasset, NY |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Relevance of fluorodopa PET scan in dopamine responsive dystonia and juvenile parkinsonism: a systematic review. | 2023 | Neurology International |
| Usefulness of 18F-FDOPA PET for the management of primary brain tumors: a systematic review of the literature. | 2020 | Cancer Imaging |
| Comparison of 5 different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma: a network meta-analysis. | 2020 | Clinical Nuclear Medicine |
| Diagnostic performance and prognostic value of PET/CT with different tracers for brain tumors: a systematic review of published meta-analyses. | 2019 | International Journal of Molecular Sciences |